Financial giants have made a conspicuous bearish move on Regeneron Pharmaceuticals. Our analysis of options history for Regeneron Pharmaceuticals (NASDAQ:REGN) revealed 12 unusual trades.
Delving into the details, we found 33% of traders were bullish, while 50% showed bearish tendencies. Out of all the trades we spotted, 7 were puts, with a value of $790,722, and 5 were calls, valued at $142,680.
Expected Price Movements
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $500.0 and $750.0 for Regeneron Pharmaceuticals, spanning the last three months.
Analyzing Volume & Open Interest
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Regeneron Pharmaceuticals's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Regeneron Pharmaceuticals's whale activity within a strike price range from $500.0 to $750.0 in the last 30 days.
Regeneron Pharmaceuticals Call and Put Volume: 30-Day Overview
Noteworthy Options Activity:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| REGN | PUT | TRADE | BULLISH | 06/18/26 | $55.4 | $49.9 | $50.0 | $700.00 | $375.0K | 3 | 100 |
| REGN | PUT | TRADE | NEUTRAL | 01/15/27 | $96.0 | $86.1 | $91.41 | $720.00 | $91.4K | 31 | 10 |
| REGN | PUT | TRADE | BEARISH | 06/18/26 | $55.0 | $51.0 | $55.0 | $700.00 | $82.5K | 3 | 15 |
| REGN | PUT | SWEEP | BEARISH | 12/26/25 | $32.3 | $29.5 | $29.6 | $750.00 | $73.8K | 34 | 25 |
| REGN | PUT | TRADE | BULLISH | 09/18/26 | $74.5 | $71.0 | $71.0 | $710.00 | $71.0K | 1 | 10 |
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
Regeneron Pharmaceuticals's Current Market Status
- With a volume of 380,377, the price of REGN is up 1.15% at $731.99.
- RSI indicators hint that the underlying stock may be approaching overbought.
- Next earnings are expected to be released in 61 days.
What The Experts Say On Regeneron Pharmaceuticals
5 market experts have recently issued ratings for this stock, with a consensus target price of $787.4.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. Click here for access. * An analyst from BMO Capital has decided to maintain their Outperform rating on Regeneron Pharmaceuticals, which currently sits at a price target of $850. * An analyst from Scotiabank persists with their Sector Perform rating on Regeneron Pharmaceuticals, maintaining a target price of $770. * An analyst from Morgan Stanley downgraded its action to Equal-Weight with a price target of $767. * An analyst from UBS has decided to maintain their Neutral rating on Regeneron Pharmaceuticals, which currently sits at a price target of $660. * In a cautious move, an analyst from HSBC downgraded its rating to Buy, setting a price target of $890.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Regeneron Pharmaceuticals options trades with real-time alerts from Benzinga Pro.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
